Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

Homologous recombination deficiency (HRD) is a common molecular signature of genomic instability and has been shown to be a biomarker for targeted therapies. However, there is a lack of studies on the role of HRD changes in lung adenocarcinoma (LUAD) transcriptomics. HRD scores were determined using...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Xu, Rongjian, Lu, Tong, Xu, Ran, Wang, Chenghao, Peng, Bo, Chang, Xiaoyan, Shen, Zhiping, Wang, Kaiyu, Shi, Jiaxin, Zhao, Jiaying, Zhang, Lin-You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496994/
https://www.ncbi.nlm.nih.gov/pubmed/37578930
http://dx.doi.org/10.18632/aging.204957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496994/
https://www.ncbi.nlm.nih.gov/pubmed/37578930
http://dx.doi.org/10.18632/aging.204957

Ejemplares similares